[go: up one dir, main page]

NO20090062L - Influensavaksine - Google Patents

Influensavaksine

Info

Publication number
NO20090062L
NO20090062L NO20090062A NO20090062A NO20090062L NO 20090062 L NO20090062 L NO 20090062L NO 20090062 A NO20090062 A NO 20090062A NO 20090062 A NO20090062 A NO 20090062A NO 20090062 L NO20090062 L NO 20090062L
Authority
NO
Norway
Prior art keywords
influenza
tocopherol
relates
monovalent
present
Prior art date
Application number
NO20090062A
Other languages
English (en)
Norwegian (no)
Inventor
Jean Stephenne
Emmanuel Jules Hanon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618195A external-priority patent/GB0618195D0/en
Priority claimed from GB0619090A external-priority patent/GB0619090D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20090062L publication Critical patent/NO20090062L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO20090062A 2006-07-17 2009-01-06 Influensavaksine NO20090062L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83143706P 2006-07-17 2006-07-17
GB0618195A GB0618195D0 (en) 2006-09-15 2006-09-15 Influenza vaccine
GB0619090A GB0619090D0 (en) 2006-09-27 2006-09-27 Influenza vaccine
PCT/EP2006/010439 WO2008009309A1 (fr) 2006-07-17 2006-10-27 Vaccin anti-grippal

Publications (1)

Publication Number Publication Date
NO20090062L true NO20090062L (no) 2009-02-16

Family

ID=37909516

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090062A NO20090062L (no) 2006-07-17 2009-01-06 Influensavaksine

Country Status (14)

Country Link
US (4) US9278127B2 (fr)
EP (1) EP2043682B1 (fr)
JP (1) JP5639760B2 (fr)
KR (1) KR101696727B1 (fr)
CO (1) CO6150191A2 (fr)
CR (1) CR10559A (fr)
EA (1) EA200900024A1 (fr)
HR (2) HRP20140488T1 (fr)
IL (1) IL196024A0 (fr)
MA (1) MA30624B1 (fr)
MX (1) MX2009000660A (fr)
NO (1) NO20090062L (fr)
PL (1) PL2043682T3 (fr)
WO (1) WO2008009309A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
KR20070116652A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을유도하는 인플루엔자 바이러스 및 수중유 에멀젼애주번트의 용도
PT2032163E (pt) 2006-06-15 2013-04-11 Novartis Ag Regime em multidoses de vacinação de influenza poupador de adjuvante
EP2043682B1 (fr) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Vaccin anti-grippal
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2589392B1 (fr) 2008-03-05 2016-11-30 Sanofi Pasteur Procédé de stabilisation d'une composition vaccinale contenant un adjuvant
CN101998990B (zh) 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
EP2310045A1 (fr) 2008-06-25 2011-04-20 Novartis AG Réactions rapides à des immunisations de rappel retardées
JP5778039B2 (ja) 2009-02-10 2015-09-16 ノバルティス アーゲー 流行関連株のためのインフルエンザワクチンレジメン
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US20110305748A1 (en) * 2010-03-11 2011-12-15 Immune Design, Corp. Vaccines for Pandemic Influenza
US20120107354A1 (en) * 2010-10-30 2012-05-03 George Dacai Liu Viral vaccine and process for preparing the same
EP2578974A1 (fr) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Chaîne de traitement pour la production de particules lyophilisées
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
EP3055412B1 (fr) 2013-10-07 2020-09-02 Seqirus UK Limited Filtre traité
KR101774203B1 (ko) 2014-07-21 2017-09-01 사노피 파스퇴르 에스에이 드롭릿 생성을 위한 액체 공급 장치
KR101729387B1 (ko) 2015-04-17 2017-04-21 경희대학교 산학협력단 곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 ｍ1-ｍ2-ｎａ-ｈａ 바이러스 유사 입자의 제조방법
EP3313438A1 (fr) * 2015-06-24 2018-05-02 Sanofi Pasteur, Inc. Méthodes d'utilisation du vaccin de la grippe pour la prévention de la pneumonie
GB201710414D0 (en) 2017-06-29 2017-08-16 Univ Nottingham Chemotherapy
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3743107A1 (fr) * 2018-01-22 2020-12-02 The United States of America, as represented by the Secretary, Department of Health and Human Services Vaccin inactivé largement protecteur contre le virus de la grippe
IL316074A (en) * 2018-04-18 2024-12-01 Biomadison Inc Compounds for determining vaccine potency
KR102103638B1 (ko) * 2018-06-01 2020-04-22 연세대학교 산학협력단 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신
EP4172897A1 (fr) * 2020-06-29 2023-05-03 Seqirus UK Limited Stocks de vaccins adaptatifs
WO2025019631A1 (fr) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Compositions immunogènes contenant un virus de la grippe a inactivé et un adjuvant oligonucléotidique cpg et leurs utilisations

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
EP0382271B1 (fr) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols comme adjuvants de vaccins
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5969109A (en) 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US5149531A (en) 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
DE4220757A1 (de) 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
CN1124013A (zh) 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
WO1994019013A1 (fr) 1993-02-19 1994-09-01 Smithkline Beecham Corporation Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (fr) 1993-10-29 1995-05-04 Pharmos Corp. Emulsions submicroniques utilisees comme adjuvants de vaccin
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3836874B2 (ja) 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
KR100682154B1 (ko) 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
EP1156781B1 (fr) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions avec des macromolecules adsorbees et microparticules
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
BR0107972A (pt) 2000-01-31 2002-11-05 Smithkline Beecham Biologicals Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1201250A1 (fr) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
WO2003084467A2 (fr) 2002-04-01 2003-10-16 Euro-Celtique S.A. Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
DE202005022108U1 (de) * 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
US7330082B2 (en) 2004-08-23 2008-02-12 Texas Instruments Incorporated Oscillator system, method of providing a resonating signal and a communications system employing the same
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
KR20070116652A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을유도하는 인플루엔자 바이러스 및 수중유 에멀젼애주번트의 용도
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US10842867B2 (en) * 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628206A1 (fr) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
AU2006310337B9 (en) * 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
EP1951301A2 (fr) * 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Emulsions a tensioactif a phase aqueuse libre pour adjuver des vaccins antigrippaux sous-unitaires
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
EP2043682B1 (fr) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Vaccin anti-grippal
US20090263422A1 (en) 2006-09-15 2009-10-22 Emmanuel Jules Hanon Influenza vaccine
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2707247A1 (fr) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Composition contre la grippe

Also Published As

Publication number Publication date
JP5639760B2 (ja) 2014-12-10
EA200900024A1 (ru) 2009-06-30
US11564984B2 (en) 2023-01-31
KR101696727B1 (ko) 2017-01-16
US20190054162A1 (en) 2019-02-21
WO2008009309A1 (fr) 2008-01-24
CR10559A (es) 2009-03-20
US20160256537A1 (en) 2016-09-08
US10555999B2 (en) 2020-02-11
EP2043682A1 (fr) 2009-04-08
US9943588B2 (en) 2018-04-17
PL2043682T3 (pl) 2014-09-30
MX2009000660A (es) 2009-04-08
EP2043682B1 (fr) 2014-04-02
MA30624B1 (fr) 2009-08-03
US20110243987A1 (en) 2011-10-06
US20200360507A1 (en) 2020-11-19
CO6150191A2 (es) 2010-04-20
KR20090029851A (ko) 2009-03-23
JP2009543816A (ja) 2009-12-10
HRP20141122T1 (hr) 2015-01-02
US9278127B2 (en) 2016-03-08
HRP20140488T1 (hr) 2014-07-04
IL196024A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
NO20090062L (no) Influensavaksine
NO20074638L (no) Ny sammensetning
Honda-Okubo et al. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses
BR112013005427A2 (pt) composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica.
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
NO20091022L (no) Vaksine omfattende en olje i vann emulsjons-adjuvant
BRPI0607374A2 (pt) vacinas de vesìculas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
PE20151588A1 (es) Vacuna contra el virus del dengue
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BRPI0621886A8 (pt) composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré-pandêmica, e, usos de um antígeno de vírus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antígeno de vírus da influenza pandêmica ou preparação antigênica do antígeno de hemaglutinina do vírus da influenza, de um vírus da influenza pandêmica ou preparação antigênica do mesmo, e de um adjuvante em emulsão óleo-em-água e de um antígeno ou preparação antigênica de uma primeira cepa de influenza
NZ568210A (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
NZ583377A (en) Method of eliciting an immune response against pandemic influenza virus
BRPI0811459A8 (pt) Preparação virossômica, uso de uma preparação virossômica, kit, e, métodos para vacinar um ser humano contra infecções de influenza, e para vacinar indivíduos mamíferos contra infecções da influenza
SG139618A1 (en) Influenza vaccine
CY1115399T1 (el) Εμβολιο γριπης
SG160386A1 (en) Novel composition
UY29430A1 (es) Nuevas composiciones inmunogénicas multivalentes contra la gripe, sus usos y procedimientos de preparación.
UY29429A1 (es) Composición inmunogénica que contiene virus de la gripe o preparación antígena del mismo, sus usos y procedimientos de preparación.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application